We are live on ! Find out more
ICM

Invenomic Capital Management Portfolio holdings

AUM $2.18B
1-Year Est. Return 0.03%
This Fund
S&P 500
This Quarter Est. Return
-4.09%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
AUM
$468M
AUM Growth
+$160M
Cap. Flow
+$174M
Cap. Flow %
37.12%
Top 10 Hldgs %
25.86%
Holding
170
New
51
Increased
61
Reduced
22
Closed
28

Top Sells

Rank Stock Value
1
DLTR icon
Dollar Tree
DLTR
+$5M
2
CIVI
Civitas Resources
CIVI
+$4.58M
3
BABA icon
Alibaba
BABA
+$4.31M
4
CNC icon
Centene
CNC
+$4.16M
5
PRU icon
Prudential Financial
PRU
+$3.94M

Sector Composition

Rank Sector Weight
1 Technology 14.78%
2 Consumer Discretionary 12.04%
3 Healthcare 11.59%
4 Financials 10.04%
5 Materials 9.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UBER icon
26
Uber
UBER
$153B
$5.5M 1.18%
131,215
+107,933
+464% +$4.65M
VMW
27
DELISTED
VMware, Inc
VMW
$5.49M 1.17%
+47,334
New +$6.22M
TROX icon
28
Tronox
TROX
$1.04B
$5.37M 1.15%
223,410
-1,541
-0.7% -$36.9K
UGI icon
29
UGI
UGI
$7.33B
$5.2M 1.11%
113,211
+40,541
+56% +$1.8M
POSH
30
DELISTED
Poshmark, Inc. Class A Common Stock
POSH
$5.14M 1.1%
+302,154
New +$6.39M
GSM icon
31
FerroAtlántica
GSM
$839M
$5.14M 1.1%
+827,839
New +$5.66M
HAL icon
32
Halliburton
HAL
$26.6B
$4.98M 1.06%
217,585
+148,689
+216% +$3.52M
MG icon
33
Mistras Group
MG
$512M
$4.84M 1.04%
651,816
+93,717
+17% +$824K
DISCK
34
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
$4.8M 1.03%
209,469
+40,613
+24% +$978K
TZOO icon
35
Travelzoo
TZOO
$75.4M
$4.76M 1.02%
504,869
+87,521
+21% +$924K
HRB icon
36
CALL
H&R Block
HRB
$5.86B
$4.71M 1.01%
200,000
FLEX icon
37
Flex
FLEX
$44.8B
$4.6M 0.98%
+332,715
New +$4.5M
ONTF
38
DELISTED
ON24
ONTF
$4.49M 0.96%
+258,615
New +$4.61M
CIVI
39
DELISTED
Civitas Resources
CIVI
$4.33M 0.93%
88,403
-86,200
-49% -$4.58M
DIN icon
40
Dine Brands
DIN
$452M
$4.25M 0.91%
56,107
+14,164
+34% +$1.15M
BHC icon
41
Bausch Health
BHC
$2.34B
$4.18M 0.89%
151,298
+19,902
+15% +$533K
CSTE icon
42
Caesarstone
CSTE
$79.5M
$4.05M 0.87%
357,285
+98,925
+38% +$1.19M
DMTK
43
DELISTED
DermTech, Inc. Common Stock
DMTK
$3.96M 0.85%
+250,786
New +$6.02M
DBX icon
44
Dropbox
DBX
$8.12B
$3.76M 0.8%
+153,066
New +$4.12M
SAMG icon
45
Silvercrest Asset Management
SAMG
$79.9M
$3.72M 0.79%
216,393
+37,543
+21% +$608K
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.69M 0.79%
+1,188,759
New +$4M
DOLE icon
47
Dole
DOLE
$1.32B
$3.66M 0.78%
+274,701
New +$3.84M
JOAN
48
DELISTED
JOANN, Inc. Common Stock
JOAN
$3.65M 0.78%
351,502
+248,750
+242% +$2.6M
HLF icon
49
Herbalife
HLF
$1.29B
$3.64M 0.78%
88,886
+1,794
+2% +$74.7K
VRN
50
DELISTED
Veren
VRN
$3.63M 0.78%
+679,570
New +$3.31M

Similar funds

Invenomic Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Invenomic Capital Management held 170 positions worth $468M, up 52% from $308M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Invenomic Capital Management deployed $174M of net new capital in Q4 2021, opening 51 new positions and adding to 61 existing holdings. Its largest new stake was AT&T: 626,014 shares worth $11.6M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 7.4% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Civitas Resources, an estimated $4.58M trimmed.

  • Invenomic Capital Management's largest Q4 2021 buy was AT&T: 626,014 shares worth $11.6M.
  • Invenomic Capital Management added most to Cigna in Q4 2021, an estimated $5.95M increase.
  • Invenomic Capital Management's biggest Q4 2021 reduction was Civitas Resources, cutting an estimated $4.58M.
  • Invenomic Capital Management fully exited Dollar Tree in Q4 2021, selling an estimated $5M.
  • Invenomic Capital Management's ten largest holdings make up 26% of its $468M portfolio in Q4 2021.
  • Invenomic Capital Management opened 51 new positions and closed 28 in Q4 2021.
  • Invenomic Capital Management's portfolio value rose 52% quarter-over-quarter to $468M.

Based on Invenomic Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.